平喘固本湯合補(bǔ)肺湯聯(lián)合頭孢他啶治療AECOPD肺腎氣虛證的臨床療效及不良反應(yīng)
關(guān)鍵詞:慢性阻塞性肺疾病急性加重期;肺腎氣虛證;平喘固本湯;補(bǔ)肺湯;頭孢他啶;不良反應(yīng) 中圖分類號:R259 文獻(xiàn)標(biāo)識碼:A DOI:10.3969/j.issn.1006-1959.2025.12.023
文章編號:1006-1959(2025)12-0112-04
linical Efficacyand Adverse Reactions of Pingchuan Guben Decoction and Bufei Decoction Combined with Ceftazidine in the Treatment of AECOPD with Lung and Kidney Qi Deficiency Syndrome
XIAO Huiqin
(DepartmentofItealedicine,DongxiangDistrictHospitalofaditionalhinseMedicine,F(xiàn)uzhouO,Jiagiina)
ceftazidineintetreametofuteexacebatioofocriepulmoarydsseEo)ingdidyidfccsdo Methodsotalof58patientsithECOdmitedtogiangDistrictHsptalofTadioalCineseedicieofFuzoufroOctob22 toDecember23eeleednddvidditocontrolgou(9patints)ndeatiogoup9patints)bydoumbertableode controlgoupastreatedwitfadeilthseatiogoreatedithngcanGubendotioomindithfeecoctio combiedidia disappearancetimeandadversereactionswerecomparedbetweenthetwogroups.ResultsTheinterventiongroupshowedsignificantlyhigher treatment efficacy than the control group( P- <0.05).Both groups showed significant decreased in TCM symptom scores(chest distension,dyspnea, coughwithexptoatio)ostreantompedtoselinhileteetioopsdsigfcantlywerCsptoostan those in the control group P<0.05) :( P< 0.05).The observationgroupalsoshowed shorterdurations in both hospital stayand symptom disappearance time than those in the control group ( Pe <0.05).No statistically significant difference was observed inthe incidenceofadversereactions between the two groups( P>0.05 ).ConclusionPinghuanGubendecoctioncombined withBufeidecoctioncombinedwithceftazidineisefectiveinthetreatmentof AECOPDwithdedcealcetore patients,and has good safety.
KeyWords:Acuteexacerbatioofchoicostructivepulmonaydisease;Lungandidneyqideficiencysydrome;PinguanGubedcoction Bufei decoction; Ceftazidine; Adverse reactions
慢性阻塞性肺疾病急性加重期(acuteexacerba-tions of chronic obstructive pulmonary disease,AE-COPD)為呼吸道常見重癥,以反復(fù)咳嗽、呼吸困難、喘息加劇等癥狀表現(xiàn)為主,其病情遷移、并發(fā)癥多,若未及時治療,可導(dǎo)致呼吸衰竭,增加患者的死亡風(fēng)險[2]。(剩余4749字)
-
-
- 醫(yī)學(xué)信息
- 2025年12期
- 基于數(shù)據(jù)挖掘技術(shù)探討艾灸治療藥...
- 基于SMOTE算法的急性缺血性...
- 高危型HPV及TCT檢測聯(lián)合篩...
- 非酒精性脂肪性肝病基因組學(xué)研究...
- 基于知識圖譜相關(guān)研究的熱點及發(fā)...
- 基于文獻(xiàn)計量分析子宮內(nèi)膜容受性...
- 四川省縣級醫(yī)院急診科建設(shè)情況調(diào)...
- 基于使能評價的全院“一張床”管...
- 某三甲中醫(yī)醫(yī)院預(yù)約掛號成功率統(tǒng)...
- 中醫(yī)藥人用經(jīng)驗數(shù)據(jù)平臺建設(shè)與應(yīng)...
- 晚期血吸蟲病病例流行病學(xué)和臨床...
- 2022年鉛山縣常住居民死因監(jiān)...
- 中性粒細(xì)胞絕對值計數(shù)與血清白蛋...
- 黔西南地區(qū)非小細(xì)胞肺癌患者發(fā)病...
- 造血干細(xì)胞移植患者特征分布...
- 甘露醇、七葉皂苷鈉聯(lián)合應(yīng)用治療...
- 替格瑞洛與氯吡格雷對急性ST段...
- 新四聯(lián)治療心衰伴心臟擴(kuò)大患者的...
- 宮頸擴(kuò)張球囊聯(lián)合間苯三酚對瘢痕...
- 右美托咪定輔助腰-硬聯(lián)合麻醉在...
- 單上前牙即拔即種即刻修復(fù)和延期...
- 血栓彈力圖指導(dǎo)和大量輸血方案在...
- 平喘固本湯合補(bǔ)肺湯聯(lián)合頭孢他啶...
- COPD患者參與共享決策現(xiàn)狀調(diào)...
- 欣母沛預(yù)防接受剖宮產(chǎn)術(shù)的妊高癥...
- 小兒肺咳顆粒聯(lián)合注射用阿奇霉素...
- 丙泊酚復(fù)合瑞芬太尼靶控輸注麻醉...
- 鋼針內(nèi)固定在開放性指骨骨折患者...
- 阿卡波糖與達(dá)格列凈治療2型糖尿...
- 血清膽紅素、蛋白與尿酸檢測對冠...
- 解毒通腑湯加減治療對闌尾炎患者...
- 綜合護(hù)理干預(yù)對尿結(jié)石患者疾病認(rèn)...
- 細(xì)節(jié)護(hù)理聯(lián)合綜合護(hù)理在泌尿外科...
- 醫(yī)護(hù)患共同決策護(hù)理對老年髖部骨...
- 綜合護(hù)理干預(yù)聯(lián)合提肛運動對痔瘡...
- 加速康復(fù)外科理念下精細(xì)化護(hù)理對...
- miRNA靶向Wnt/β-ca...
- 陳舊性下尺橈關(guān)節(jié)脫位治療研究進(jìn)...
- 線粒體自噬在缺血性卒中的研究現(xiàn)...
- 玫瑰痤瘡發(fā)病機(jī)制及不同藥物治療...